SARS-CoV-2 3CL protease (3CLpro) in complex with nirmatrelvir

PF-07321332, bound form; nirmatrelvir, bound form; Paxlovid, bound form

Discovery of oral simnotrelvir, an approved SARS-CoV-2 3C-like protease inhibitor for the treatment of COVID-19

3CL-PRO,3CLp,Main protease,Mpro,Non-structural protein 5,nsp5,SARS coronavirus main proteinase

Severe acute respiratory syndrome coronavirus 2